GBNH.F Stock Overview
Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Greenbrook TMS Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.016 |
| 52 Week High | US$0.64 |
| 52 Week Low | US$0.006 |
| Beta | 1.38 |
| 11 Month Change | 45.45% |
| 3 Month Change | 28.51% |
| 1 Year Change | -93.93% |
| 33 Year Change | -99.72% |
| 5 Year Change | -99.80% |
| Change since IPO | -99.86% |
Recent News & Updates
Shareholder Returns
| GBNH.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -20.0% | 1.6% | 2.2% |
| 1Y | -93.9% | 2.1% | 31.7% |
Return vs Industry: GBNH.F underperformed the US Healthcare industry which returned 2.9% over the past year.
Return vs Market: GBNH.F underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| GBNH.F volatility | |
|---|---|
| GBNH.F Average Weekly Movement | 51.3% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GBNH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GBNH.F's weekly volatility has increased from 46% to 51% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 514 | Bill Leonard | www.greenbrooktms.com |
Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared neurostimulation therapy for the treatment of major depressive disorder and other mental health disorders. The company also offers Spravato, an esketamine nasal spray; and other treatment modalities for the treatment of depression and related psychiatric services.
Greenbrook TMS Inc. Fundamentals Summary
| GBNH.F fundamental statistics | |
|---|---|
| Market cap | US$2.63m |
| Earnings (TTM) | -US$52.20m |
| Revenue (TTM) | US$75.21m |
0.0x
P/S Ratio-0.1x
P/E RatioIs GBNH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBNH.F income statement (TTM) | |
|---|---|
| Revenue | US$75.21m |
| Cost of Revenue | US$73.94m |
| Gross Profit | US$1.28m |
| Other Expenses | US$53.48m |
| Earnings | -US$52.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 1.70% |
| Net Profit Margin | -69.41% |
| Debt/Equity Ratio | -104.8% |
How did GBNH.F perform over the long term?
See historical performance and comparison